<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>A case of angiographically-documented embolism is presented in a patient using oral contraceptives (OC) with marked <z:hpo ids='HP_0001634'>mitral valve prolapse</z:hpo> (MVP) and an atrial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>OC use has been shown to decrease levels of antithrombin III and increase platelet coagulant activity </plain></SENT>
<SENT sid="2" pm="."><plain>This increased coagulability may increase the risk of intra-atrial <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> formation and subsequent <z:e sem="disease" ids="C0007780" disease_type="Disease or Syndrome" abbrv="">cerebral embolism</z:e> in patients with MVP </plain></SENT>
<SENT sid="3" pm="."><plain>We believe that MVP, especially when redundant valve leaflets are recognized, may be a relative contraindication to OC use </plain></SENT>
</text></document>